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Abstract
Background: Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded
automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we
retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC
patients being treated with enzalutamide.
Methods: Retrospectively, we included patients who received enzalutamide as a clinically approved therapy for
mCRPC and had undergone bone scan prior to starting therapy. Automated BSI, prostate-specific antigen (PSA),
hemoglobin (HgB), and alkaline phosphatase (ALP) were obtained at baseline. Change in automated BSI and PSA
were obtained from patients who have had bone scan at week 12 of treatment follow-up. Automated BSI was
obtained using the analytically validated EXINI BoneBSI version 2. Kendall’s tau (τ) was used to assess the correlation of
BSI with other blood-based biomarkers. Concordance index (C-index) was used to evaluate the discriminating strength
of automated BSI in predicting OS.
Results: Eighty mCRPC patients with baseline bone scans were included in the study. There was a weak correlation of
automated BSI with PSA (τ = 0.30), with HgB (τ = −0.17), and with ALP (τ = 0.56). At baseline, the automated BSI was
observed to be predictive of OS (C-index 0.72, standard error (SE) 0.03). Adding automated BSI to the blood-based
model significantly improved the C-index from 0.67 to 0.72, p = 0.017. Treatment follow-up bone scans were available
from 62 patients. Both change in BSI and percent change in PSA were predictive of OS. However, the combined
predictive model of percent PSA change and change in automated BSI (C-index 0.77) was significantly higher than that
of percent PSA change alone (C-index 0.73), p = 0.041.
Conclusions: The upgraded and analytically validated automated BSI was found to be a strong predictor of OS in
mCRPC patients. Additionally, the change in automated BSI demonstrated an additive clinical value to the change in
PSA in mCRPC patients being treated with enzalutamide.
Keywords: Bone Scan Index (BSI), Imaging biomarker, Bone scan, Enzalutamide, Metastatic castration-resistant prostate
cancer (mCRPC)
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Background
Bone metastasis is present in 90 % of patients with
metastatic castration-resistant prostate cancer (mCRPC)
[1]. In such patients, the bone scan is the standard im-
aging modality to assess change in skeletal disease bur-
den. However, the interpretation of the bone scan has
significant limitations. The qualitative manual assess-
ment of the bone scan is dependent on the skill and ex-
pertise of the local reader. Additionally, the criteria of
counting new lesions to identify disease progression do
not account for changes in disease distribution, increase
in disease burden of existing lesions, or increase in conflu-
ent disease. Therefore, there is a need to qualify a fully
quantitative assessment of disease burden in bone to de-
tect post-treatment changes that are clinically relevant.
The manual Bone Scan Index (BSI), developed at the
Memorial Sloan Kettering Cancer Center, is a fully quan-
titative assessment of bone scans that accounts for the
metastatic lesions, as the percentage of total skeletal
mass [2]. The manual BSI and its changes at treatment
follow-up have been shown to have a significant associ-
ation with overall survival (OS) [3, 4]. Despite showing
its clinical utility, the manual BSI has not been adopted
in routine clinical practice due to the laborious process
of manual calculations.
To overcome the limitations of manual assessment,
the BSI methodology was automated using a computer-
ized image analysis system that employed an artificial
neural network [5]. With the computer automation, the
time of detecting metastatic lesion and calculating the
BSI was reduced from an average 20 min (by an experi-
enced reader) to 5 s per patient.
Recently, in a multi-institutional effort, we performed
the analytical validation of an upgraded automated BSI
platform in assessing change in bone scan of metastatic
prostate cancer [6]. The consistent linearity of the
upgraded BSI platform overcame the limitation of its
predecessor in underestimating the BSI values in pa-
tients with a higher (>5 BSI) tumor burden [7]. Add-
itionally, the upgraded automated BSI demonstrated that
with minimal manual supervision, it can standardize the
inter-operator variability in the assessment of change in
bone scan. The result demonstrated the reliability of au-
tomated BSI in assessing change in bone scan and
served as the foundation for future clinical studies.
Treatment with enzalutamide has shown to improve
progression free survival and prolong OS in patients
with mCRPC [8, 9]. In this hypothesis-generating retro-
spective study, we assessed the discriminatory strength
of the upgraded automated BSI in predicting OS in
mCRPC patients being treated with enzalutamide. As a
part of the clinical qualification effort, the study here is
aimed to provide justification for prospective validation
of the upgraded and analytically validated automated BSI
as a first quantitative imaging biomarker that can add
clinical value to the treatment management of the
mCRPC patients.
Methods
Study design
The retrospective study would aim to generate the hy-
pothesis, for prospective validation, that as an imaging
biomarker the automated BSI values provide distinct in-
formation and have an additive clinical value over the
available blood-based markers. To evaluate the auto-
mated BSI as a marker with distinct information, the
values of the BSI were associated with the values of the
blood-based markers. To evaluate the additive clinical
value of automated BSI, discriminatory strength of the
blood-based biomarkers was assessed with and without
the addition of automated BSI values in predicting OS of
mCRPC patients being treated with enzalutamide.
Patients
All mCRPC patients who initiated treatment with Food
and Drug Administration (FDA)-approved enzalutamide,
from December 2012 to December 2014, at Skåne Uni-
versity Hospital in Malmö, Sweden, and at Copenhagen
University Hospital (Rigshospitalet) in Copenhagen,
Denmark, were considered for the study. CRPC was
defined as the patients who had failed androgen
deprivation therapy and had been clinically documented
to have prostate-specific antigen (PSA) and/or radio-
logical progression despite castrate level of testosterone
(<20 ng/dL). Prior radiological scans were used to con-
firm the presence of metastasis. The mCRPC patients,
who had undergone bone scan, as part of the clinical
routine, before initiating enzalutamide treatment, were
enrolled in the retrospective analysis. In these patients,
we retrospectively collected the PSA, hemoglobin (HgB),
and alkaline phosphatase (ALP) prior to initiating treat-
ment with enzalutamide. Change in automated BSI and
percent change in PSA were obtained from patients who
had bone scan available at 12 week (±4 weeks) of treat-
ment follow-up.
The retrospective study was performed in accordance
with the Declaration of Helsinki. The ethical permission
for the retrospective study and individual patient consent
was obtained at the regional ethical review board at Lund
University, Sweden, and at Rigshospitalet, Denmark.
Bone scan
The whole-body bone scan was obtained after 3 h of a
single intravenous injection of 600 MBq Tc-99m methy-
lene diphosphonate. Whole-body images with anterior
and posterior views (scan speed 10 cm/min, 256 × 1024
matrix) were obtained using a gamma camera equipped
with low-energy, high-resolution parallel hole collimators
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(Maxxus; General Electric, Milwaukee, WI, USA
(Malmö); Precedence; Philips Healthcare, Eindhoven,
The Netherlands (Copenhagen)). Energy discrimination
was provided by a 15 % window centered on the
140 keV of Tc-99m.
Automated BSI analysis
The upgraded EXINI BoneBSI software (version 2), devel-
oped by EXINI Diagnostics AB (Lund, Sweden), was
used to analyze the retrospectively collected bone scans
and to generate automated BSI. The methodology of the
automated platform has been described in detail in a
previous study [7]. In summary, the different anatomical
regions of the skeleton are segmented followed by detec-
tion and classification of the abnormal hotspots as meta-
static lesions. The weight fraction of the skeleton for
each metastatic hotspot is calculated, and the BSI is cal-
culated as the sum of all such fractions.
Statistical analysis
As a hypothesis generating retrospective study, no prior
assumptions were made for the clinical utility of auto-
mated BSI to render power calculations. To evaluate the
automated BSI as a distinct and independent variable,
we used the Kendall’s tau (τ) and the Spearman’s rank
correlation coefficient to determine the association be-
tween automated BSI and other blood-based biomarkers.
Kendall’s tau and the Spearman’s rank correlation are
the two available non-parametric rank correlations that
measure the strength of association between two separ-
ate variables.
Kaplan Meier method was used to estimate the me-
dian OS of the baseline and of the treatment follow-up
patient cohorts. Concordance index (C-index) and its
standard error (SE) was used to evaluate the discrimin-
atory strength of the automated BSI in predicting OS
[10]. To determine the additive strength of automated
BSI as a biomarker, we compared the discrimination, C-
index values [11], of the blood-based model to that of
the blood-based model incorporating the automated BSI.
C-index would allow the evaluation of the additive clin-
ical value of automated BSI as a continuous covariate
over the blood biomarkers, without stratifying the data
with an arbitrary threshold. A strong concordance would
indicate that the covariate is highly informative in pre-
dicting the relative risk of death between any two pa-
tients at a given time. Statistical significance for each
statistical test was set at 0.05 (two-tailed). All statistical
analyses were performed using R software version 3.1.2.
Results
Patients
Eighty of the eligible mCRPC patients had their baseline
bone scans available for automated BSI analysis with
median follow-up time of 56 weeks. Sixty-two of the
eighty mCRPC patients had available bone scans at week
12 of treatment follow-up. Figure 1 illustrates the evalu-
able patients available at baseline and at treatment
follow-up. The demographics, prior treatment history
and baseline characteristics of the evaluable mCRPC pa-
tients are summarized in Table 1.
Baseline analysis
The Kendall’s tau correlations and Spearman correlation
of the automated BSI with the blood-based biomarkers
are detailed in Table 2. There was a weak correlation ob-
served between automated BSI and all the available
blood-based biomarkers (N = 80). With 56 (70 %) events,
the median survival time for the 80 patients was
59 weeks (95 % confidence interval, 34–84 weeks). The
C-index analysis at baseline of the 80 mCRPC patients
are summarized in Table 3 (A). The automated BSI at
baseline was observed to be predictive of OS (C-index
0.72). The addition of the automated BSI to the blood-
based model that included PSA, ALP, and HgB signifi-
cantly improved the C-index increased from 0.67 to
0.72, p = 0.017.
Treatment follow-up analysis
Change in the automated BSI (median = 0.05, interquartile
range = [−] 0.28–1.43) and the percent change in PSA
(median = [−] 0.60, interquartile range = [−] 0.86–[−] 0.12)
at treatment follow-up was calculated in all 62 patients.
An example of the BSI and PSA change at treatment
follow-up is shown in Fig. 2. The median survival time for
62 patients, with treatment follow-up data, was 83 weeks
(95 % confidence interval, 59–163 weeks). The C-index
analysis of on-treatment change in BSI and PSA is shown
in Table 3 (B). The combined predictive model of percent
PSA change and change in automated BSI (C-index 0.77)
was observed to be significantly higher than that of per-
cent PSA change alone (C-index 0.73), p = 0.041.
Discussion
Bone scan remains the standard imaging modality to as-
sess radiographic progression-free survival in patients
with mCRPC. As a primary endpoint, the progression-
free survival has been accepted by FDA to show the
treatment efficacy of novel therapy in patients with
mCRPC [12]. There is an unmet need for a quantitative
and a reproducible assessment of bone scan that gener-
ate reliable data in multi-institutional registration trials.
The study presented here is an incremental progress of the
automated BSI towards its qualification as an imaging bio-
marker with clinical relevance in mCRPC patients. Com-
pared to its predecessor, which underestimated the BSI
values in patients with a high tumor burden (>5 BSI), the
upgraded EXINI BoneBSI (version 2) platform generates a
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consistent BSI assessment for patient with low and high
tumor burdens. The performance of the commercially
available platform was recently evaluated in a multi-
institutional analytical validation study [6]. In this
hypothesis-generating study, we have demonstrated
that the upgraded automated BSI is a strong predictor
of OS with an additive clinical value to the existing
blood-based biomarkers.
In baseline survival analysis, our study demonstrated
that the automated BSI was predictive of OS (C-index
0.72). The independent and additive clinical value of au-
tomated BSI was demonstrated in the significant im-
provement of the blood-based model’s discrimination in
predicting OS (C-index from 0.67 to 0.72). Additionally,
the weak correlation between the automated BSI and the
blood-based biomarkers implied that the automated BSI
is an independent marker with distinct quantitative in-
formation that can add to the clinical evaluation of
Table 1 Demographic and clinical history of patients that
qualified for the survival analysis
Demographics Patients evaluable
at baseline
Patients evaluable at 12-week
treatment follow-up
(N = 80) (N = 62)
Median (range)
Age 71 (54–84) 71 (54–84)
PSA at diagnosis 46 (3.7–4625) 46 (3.7–1018)
Primary treatment N (%)
Radiation therapy 22 (28) 19 (30)
Radical prostatectomy 13 (16) 9 (15)
Prior systemic
treatment
Prior ADT 80 (100) 62 (100)
Prior chemo 64 (80) 47 (75)
Covariates Median (range)
PSA (ng/mL) 157.5 (1.1–5460) 149 (1.1–5460)
ALP (U/L) 124.3 (41.2–1058) –
HgB (mmol/L) 7.5 (5.2–10.0) –
BSI 2.7 (0.01–21.11) 2.6 (0.01–21.11)
N (%)
Deaths 56 (70) 40 (65)
Fig. 1 Flow chart of evaluable patients available for analyses
Table 2 Non-parametric Kendall’s tau and Spearman correlation
of automated BSI against blood-based biomarkers (N = 80)
Blood-based
biomarkers
Kendall’s tau
(against BSI)
p value Spearman
(against BSI)
p value
PSA 0.30 0.00015 0.41 0.00011
ALP 0.56 <0.0001 0.64 <0.0001
HgB −0.17 0.0272 −0.25 0.0265
Anand et al. EJNMMI Research  (2016) 6:23 Page 4 of 7
patients with skeletal metastasis. Our data supports the
initial findings of the original manual BSI studies that
have demonstrated significant and strong association
with OS in patients with mCRPC [3]. The data is also in
agreement with the previous version of a computer-
automated BSI platform that demonstrated the prognos-
tic value of the automated BSI in newly diagnosed and
in mCRPC patients [7, 13]. The result should encourage
investigators to evaluate the role of automated BSI in
existing prognostic models for metastatic prostate can-
cer, which noticeably lacked a quantitative imaging
parameter indicative of skeletal disease burden [1, 14].
The baseline analysis in our study was limited by the
unavailability of lactate dehydrogenase and albumin,
both of which have demonstrated an association with
OS and are part of the baseline prognostic model in
mCRPC patients.
Enzalutamide prevents the translocation of the andro-
gen receptor to nucleus that prevents the activation of
some proliferative genes, which includes PSA. In its
registration studies, enzalutamide has shown improve-
ment in OS with early measure of response shown by
percent PSA decline at week 12 [8, 15]. In agreement to
Table 3 A: C-index analysis of with and without the addition of
BSI to blood based biomarkers at baseline. B: C-index analysis of
change in BSI and PSA at treatment follow-up
C-index Confidence interval SE
A. Baseline analysisa
(dead/total = 56/80)
BSI 0.71 0.64–0.77 0.03
PSA 0.65 0.57–0.72 0.03
ALP 0.67 0.58–0.75 0.03
HgB 0.26 0.20–0.32 0.03
PSA + ALP + HgB 0.67 0.58–0.74 0.03
PSA + ALP + HgB + BSI 0.72 0.64–0.78 0.03
B. Change (Δ) at week 12
(dead/total = 40/62)
Δ BSI 0.75 0.68–0.81 0.05
Δ PSA 0.73 0.66–0.78 0.05
Δ PSA + Δ BSI 0.77 0.71–0.82 0.05
aBSI, PSA, ALP, and HgB values were observed skewed and therefore
logarithmically transformed
Anterior AnteriorPosterior Posterior
Pre-Treatment Treatment Follow-up
BSI: 5.84 PSA:283 BSI: 3.83 PSA:18  
Fig. 2 Illustrative example of BSI analysis and PSA change after treatment with enzalutamide at 12-week treatment follow-up. Lesions detected
and classified as metastatic by the neural network of the automated EXINI platform for BSI calculation are highlighted in red
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these studies, we observed a marked decrease in per-
cent PSA change at week 12 of treatment with enzalu-
tamide (median = [−] 0.60, IQR = [−] 0.12–[−] 0.86).
The study also demonstrated that the combined model,
including the change in automated BSI and the percent
change in PSA, was significantly stronger in discrimin-
ating for OS than the percent change in PSA alone.
The data is unique in its attempt to establish that with
consistent linearity, the change in automated BSI of
the upgraded platform is not only reproducible but is
also clinically relevant. In Japan, Mitsui et al. has
similarly demonstrated improvement in C-index with
addition of automated BSI to PSA (from 0.62 to 0.66)
[16]. However, it should be noted that the platform
used in the Mitsui et al. work, BONENAVI®, has been
uniquely trained on a data set consisting exclusively of
Japanese patients and therefore caters to a distinct
population base [17].
As an indirect measurement of disease burden, PSA
and bone scan lesions are known to increase temporarily
within few weeks of response to an effective therapy.
This increase, specifically observed in bone scan, is com-
monly referred to as flare phenomenon. Comprehensive
investigations in patients with metastatic prostate cancer
have shown the flare to peak at weeks 6–8 of treatment
follow-up [18, 19]. Therefore, Prostate Cancer Working
Group 2 (PCWG2) criteria recommend that early
changes (before 12 weeks) in PSA and radionuclide bone
scan should be ignored [20]. Although the evidence of
the flare phenomenon in mCRPC patients being treated
with enzalutamide is quite limited, if not non-existent,
the current study evaluated the change in automated
BSI and in PSA at week 12 of treatment follow-up.
Following the PCWG2 recommendation, the analysis at
week 12 of treatment follow-up minimizes but does not
overcome the risk of flare and its limitation on the clin-
ical evaluation of automated BSI.
The current study was limited in its scope as a retro-
spective analysis. However, with its enrollment criteria,
the study was controlled for the standardized time point
analysis at pre-treatment and at 12-week treatment
follow-up for each of the respective covariates. A reason-
able large number of patients were included from the
two separate hospitals to avoid site selection biases. The
data presented here, using an upgraded and analytically
validated platform, confirms the original clinical findings
of the manual BSI studies. More importantly, the study
is part of the continual effort to clinically validate auto-
mated BSI as an imaging biomarker to quantify the
change in total skeletal tumor burden that is clinically
relevant. The computer-automated BSI represents an
opportunity to realize the clinical potential of a standard
imaging modality, bone scan, which has been limited by
the variability of visual assessment.
Conclusions
In the present study, our data has demonstrated that the
analytically validated automated BSI is an independent and
a strong predictor of OS in mCRPC patients. The study
also found that the change in automated BSI has an addi-
tive clinical value to the change in PSA in mCRPC patients
being treated with enzalutamide. The data presented here
confirms the initial findings of the original manual BSI
studies and serve as the foundation for future prospective
studies aimed to clinically validate automated BSI as an
imaging biomarker in mCRPC patients.
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